Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 361,457 | 396,149 | 645,361 | 202,045 | 408,671 |
| Marketable Securities | 1,086,209 | 1,171,715 | 1,045,257 | 746,249 | 514,600 |
| Receivables | 2,961 | 50,768 | 34,002 | 14,644 | 15,405 |
| TOTAL | $1,502,559 | $1,685,297 | $1,764,740 | $993,368 | $960,709 |
| Non-Current Assets | |||||
| PPE Net | 227,839 | 201,979 | 181,900 | 161,899 | 147,533 |
| Investments And Advances | 44,825 | 30,648 | 43,919 | 201,543 | 324,570 |
| Other Non-Current Assets | 14,166 | 5,215 | 4,171 | 1,471 | 1,471 |
| TOTAL | $286,830 | $237,842 | $229,990 | $364,913 | $473,574 |
| Total Assets | $1,789,389 | $1,923,139 | $1,994,730 | $1,358,281 | $1,434,283 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,988 | 13,206 | 28,355 | 9,239 | 23,170 |
| Accrued Expenses | 89,867 | 63,824 | 72,203 | 51,260 | 43,820 |
| TOTAL | $113,659 | $115,383 | $144,251 | $101,045 | $108,726 |
| Non-Current Liabilities | |||||
| Long Term Debt | 30,000 | 30,000 | 30,000 | 150,000 | 150,000 |
| Deferred Revenues | 11,804 | 38,353 | 43,693 | 40,546 | 41,736 |
| Other Non-Current Liabilities | 4,186 | 4,458 | 4,347 | 2,842 | 2,815 |
| TOTAL | $54,928 | $52,951 | $84,048 | $198,401 | $202,591 |
| Total Liabilities | $168,587 | $168,334 | $228,299 | $299,446 | $311,317 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 100,666 | 100,522 | 99,868 | 92,731 | 91,733 |
| Common Shares | 1,005 | 1,005 | 997 | 924 | 917 |
| Retained earnings | -2,384,249 | -2,220,689 | -2,147,685 | -2,005,458 | -1,882,521 |
| Other shareholders' equity | -33,807 | -34,853 | -34,433 | -33,741 | -33,959 |
| TOTAL | $1,620,802 | $1,754,805 | $1,766,431 | $1,058,835 | $1,122,966 |
| Total Liabilities And Equity | $1,789,389 | $1,923,139 | $1,994,730 | $1,358,281 | $1,434,283 |